Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

Next Previous
Trial Profile

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DT 2216 (Primary) ; Irinotecan (Primary)
  • Indications Carcinoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 19 Nov 2025 According to the Dialectic Therapeutics media release, Dr. Stover, the principal investigator of the study.
  • 19 Nov 2025 According to the Dialectic Therapeutics media release, company announced that patient dosing is underway.
  • 05 Jun 2025 Planned initiation date (estimated date of first participant enrollment) changed from 20 Jun 2025 to 21 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top